Global Oncology Pharmaceuticals Market
Global Oncology Pharmaceuticals Market

Oncology Pharmaceuticals Comprehensive Study by Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), Application (Breast Cancer, Blood Cancer, Colorectal, Melanoma, Others) Players and Region - Global Market Outlook to 2024

Oncology Pharmaceuticals Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jul 2019 Edition 223 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Cancer treatment has a well focus on personalized medicine, leading to patient segmentation based on biomarker status. Major cancer types are lung, breast, colorectal (CRC), melanoma which become increasingly segmented, with each segment now being recognized as having specific treatment options and consequences. Oncology remains to be an area of active interest with a healthy pipeline of which 87% is a targeted therapy, several of the targeted therapies in development have an associated biomarker . Future oncology cost growth is expected to be in the range of 6% to 9%, annually, through 2021. The pipeline of oncology drugs in medical development has extended by 45% over the past ten years.

The market study is being classified by Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Others), by Application (Breast Cancer, Blood Cancer, Colorectal, Melanoma and Others) and major geographies with country level break-up.

Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Celgene Corporation (United States), Janssen Pharmaceutical (Belgium), Bristol-Myers Squibb (United States), Pfizer Inc. (United States), Merck & Co. (United States), Eli Lilly and Company (United States), AbbVie, Inc. (United States), AstraZeneca plc. (United Kingdom), Bayer AG (Germany) and Amgen Inc. (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oncology Pharmaceuticals market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Oncology Pharmaceuticals market by Type, Application and Region.

On the basis of geography, the market of Oncology Pharmaceuticals has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Switzerland, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Drivers
  • Rising Spending On Therapeutic and Supportive Care for Cancer
  • Increase in Treatment Options That Have Helped To Lengthen Lives

Market Trend
  • Rapid Uptake of Immuno-Oncology Drugs

Restraints
  • Adverse Effects Associated With the Use of Cancer Drugs

Opportunities
  • Increasing Product Approvals by Regulatory Bodies for the Treatment of Various Cancers

Challenges
  • High Costs of Oncology Therapeutics and Complexity in Cancer Treatments


Market Leaders and their expansionary development strategies
On July 1, 2019 Novartis has announced that it has completed its acquisition of Xiidra, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
On May 2, 2019- Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, has announced a precision medicine collaboration in oncology. Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. and July 2, 2019- Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.


Key Target Audience
Manufacturers of Oncology Drugs, Suppliers of Oncology Drugs, Wholesalers, Distributors and Retailers of Oncology Drugs, Healthcare Industry, Research Institutes and Governmental Bodies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others
By Application
  • Breast Cancer
  • Blood Cancer
  • Colorectal
  • Melanoma
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Switzerland
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Spending On Therapeutic and Supportive Care for Cancer
      • 3.2.2. Increase in Treatment Options That Have Helped To Lengthen Lives
    • 3.3. Market Challenges
      • 3.3.1. High Costs of Oncology Therapeutics and Complexity in Cancer Treatments
    • 3.4. Market Trends
      • 3.4.1. Rapid Uptake of Immuno-Oncology Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncology Pharmaceuticals, by Type, Application and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Oncology Pharmaceuticals (Value)
      • 5.2.1. Global Oncology Pharmaceuticals by: Type (Value)
        • 5.2.1.1. Chemotherapy
        • 5.2.1.2. Targeted Therapy
        • 5.2.1.3. Immunotherapy
        • 5.2.1.4. Hormonal Therapy
        • 5.2.1.5. Others
      • 5.2.2. Global Oncology Pharmaceuticals by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Blood Cancer
        • 5.2.2.3. Colorectal
        • 5.2.2.4. Melanoma
        • 5.2.2.5. Others
      • 5.2.3. Global Oncology Pharmaceuticals Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Switzerland
          • 5.2.3.3.7. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Oncology Pharmaceuticals (Volume)
      • 5.3.1. Global Oncology Pharmaceuticals by: Type (Volume)
        • 5.3.1.1. Chemotherapy
        • 5.3.1.2. Targeted Therapy
        • 5.3.1.3. Immunotherapy
        • 5.3.1.4. Hormonal Therapy
        • 5.3.1.5. Others
      • 5.3.2. Global Oncology Pharmaceuticals by: Application (Volume)
        • 5.3.2.1. Breast Cancer
        • 5.3.2.2. Blood Cancer
        • 5.3.2.3. Colorectal
        • 5.3.2.4. Melanoma
        • 5.3.2.5. Others
      • 5.3.3. Global Oncology Pharmaceuticals Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Switzerland
          • 5.3.3.3.7. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Oncology Pharmaceuticals (Price)
      • 5.4.1. Global Oncology Pharmaceuticals by: Type (Price)
  • 6. Oncology Pharmaceuticals: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceutical (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc. (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bayer AG (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Amgen Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Oncology Pharmaceuticals Sale, by Type, Application and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Oncology Pharmaceuticals (Value)
      • 7.2.1. Global Oncology Pharmaceuticals by: Type (Value)
        • 7.2.1.1. Chemotherapy
        • 7.2.1.2. Targeted Therapy
        • 7.2.1.3. Immunotherapy
        • 7.2.1.4. Hormonal Therapy
        • 7.2.1.5. Others
      • 7.2.2. Global Oncology Pharmaceuticals by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Blood Cancer
        • 7.2.2.3. Colorectal
        • 7.2.2.4. Melanoma
        • 7.2.2.5. Others
      • 7.2.3. Global Oncology Pharmaceuticals Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Switzerland
          • 7.2.3.3.7. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Oncology Pharmaceuticals (Volume)
      • 7.3.1. Global Oncology Pharmaceuticals by: Type (Volume)
        • 7.3.1.1. Chemotherapy
        • 7.3.1.2. Targeted Therapy
        • 7.3.1.3. Immunotherapy
        • 7.3.1.4. Hormonal Therapy
        • 7.3.1.5. Others
      • 7.3.2. Global Oncology Pharmaceuticals by: Application (Volume)
        • 7.3.2.1. Breast Cancer
        • 7.3.2.2. Blood Cancer
        • 7.3.2.3. Colorectal
        • 7.3.2.4. Melanoma
        • 7.3.2.5. Others
      • 7.3.3. Global Oncology Pharmaceuticals Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Switzerland
          • 7.3.3.3.7. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Oncology Pharmaceuticals (Price)
      • 7.4.1. Global Oncology Pharmaceuticals by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncology Pharmaceuticals: by Type(USD Million)
  • Table 2. Oncology Pharmaceuticals Chemotherapy , by Region USD Million (2013-2018)
  • Table 3. Oncology Pharmaceuticals Targeted Therapy , by Region USD Million (2013-2018)
  • Table 4. Oncology Pharmaceuticals Immunotherapy , by Region USD Million (2013-2018)
  • Table 5. Oncology Pharmaceuticals Hormonal Therapy , by Region USD Million (2013-2018)
  • Table 6. Oncology Pharmaceuticals Others , by Region USD Million (2013-2018)
  • Table 7. Oncology Pharmaceuticals: by Application(USD Million)
  • Table 8. Oncology Pharmaceuticals Breast Cancer , by Region USD Million (2013-2018)
  • Table 9. Oncology Pharmaceuticals Blood Cancer , by Region USD Million (2013-2018)
  • Table 10. Oncology Pharmaceuticals Colorectal , by Region USD Million (2013-2018)
  • Table 11. Oncology Pharmaceuticals Melanoma , by Region USD Million (2013-2018)
  • Table 12. Oncology Pharmaceuticals Others , by Region USD Million (2013-2018)
  • Table 13. South America Oncology Pharmaceuticals, by Country USD Million (2013-2018)
  • Table 14. South America Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 15. South America Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 16. Brazil Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 17. Brazil Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 18. Argentina Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 19. Argentina Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 20. Rest of South America Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 21. Rest of South America Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 22. Asia Pacific Oncology Pharmaceuticals, by Country USD Million (2013-2018)
  • Table 23. Asia Pacific Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 24. Asia Pacific Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 25. China Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 26. China Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 27. Japan Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 28. Japan Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 29. India Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 30. India Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 31. South Korea Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 32. South Korea Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 33. Taiwan Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 34. Taiwan Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 35. Australia Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 36. Australia Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 37. Rest of Asia-Pacific Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 38. Rest of Asia-Pacific Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 39. Europe Oncology Pharmaceuticals, by Country USD Million (2013-2018)
  • Table 40. Europe Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 41. Europe Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 42. Germany Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 43. Germany Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 44. France Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 45. France Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 46. Italy Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 47. Italy Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 48. United Kingdom Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 49. United Kingdom Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 50. Netherlands Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 51. Netherlands Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 52. Switzerland Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 53. Switzerland Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 54. Rest of Europe Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 55. Rest of Europe Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 56. MEA Oncology Pharmaceuticals, by Country USD Million (2013-2018)
  • Table 57. MEA Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 58. MEA Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 59. Middle East Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 60. Middle East Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 61. Africa Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 62. Africa Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 63. North America Oncology Pharmaceuticals, by Country USD Million (2013-2018)
  • Table 64. North America Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 65. North America Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 66. United States Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 67. United States Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 68. Canada Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 69. Canada Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 70. Mexico Oncology Pharmaceuticals, by Type USD Million (2013-2018)
  • Table 71. Mexico Oncology Pharmaceuticals, by Application USD Million (2013-2018)
  • Table 72. Oncology Pharmaceuticals Sales: by Type(K Tons)
  • Table 73. Oncology Pharmaceuticals Sales Chemotherapy , by Region K Tons (2013-2018)
  • Table 74. Oncology Pharmaceuticals Sales Targeted Therapy , by Region K Tons (2013-2018)
  • Table 75. Oncology Pharmaceuticals Sales Immunotherapy , by Region K Tons (2013-2018)
  • Table 76. Oncology Pharmaceuticals Sales Hormonal Therapy , by Region K Tons (2013-2018)
  • Table 77. Oncology Pharmaceuticals Sales Others , by Region K Tons (2013-2018)
  • Table 78. Oncology Pharmaceuticals Sales: by Application(K Tons)
  • Table 79. Oncology Pharmaceuticals Sales Breast Cancer , by Region K Tons (2013-2018)
  • Table 80. Oncology Pharmaceuticals Sales Blood Cancer , by Region K Tons (2013-2018)
  • Table 81. Oncology Pharmaceuticals Sales Colorectal , by Region K Tons (2013-2018)
  • Table 82. Oncology Pharmaceuticals Sales Melanoma , by Region K Tons (2013-2018)
  • Table 83. Oncology Pharmaceuticals Sales Others , by Region K Tons (2013-2018)
  • Table 84. South America Oncology Pharmaceuticals Sales, by Country K Tons (2013-2018)
  • Table 85. South America Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 86. South America Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 87. Brazil Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 88. Brazil Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 89. Argentina Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 90. Argentina Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 91. Rest of South America Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 92. Rest of South America Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 93. Asia Pacific Oncology Pharmaceuticals Sales, by Country K Tons (2013-2018)
  • Table 94. Asia Pacific Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 95. Asia Pacific Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 96. China Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 97. China Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 98. Japan Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 99. Japan Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 100. India Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 101. India Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 102. South Korea Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 103. South Korea Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 104. Taiwan Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 105. Taiwan Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 106. Australia Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 107. Australia Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 108. Rest of Asia-Pacific Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 109. Rest of Asia-Pacific Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 110. Europe Oncology Pharmaceuticals Sales, by Country K Tons (2013-2018)
  • Table 111. Europe Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 112. Europe Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 113. Germany Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 114. Germany Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 115. France Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 116. France Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 117. Italy Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 118. Italy Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 119. United Kingdom Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 120. United Kingdom Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 121. Netherlands Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 122. Netherlands Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 123. Switzerland Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 124. Switzerland Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 125. Rest of Europe Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 126. Rest of Europe Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 127. MEA Oncology Pharmaceuticals Sales, by Country K Tons (2013-2018)
  • Table 128. MEA Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 129. MEA Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 130. Middle East Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 131. Middle East Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 132. Africa Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 133. Africa Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 134. North America Oncology Pharmaceuticals Sales, by Country K Tons (2013-2018)
  • Table 135. North America Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 136. North America Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 137. United States Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 138. United States Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 139. Canada Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 140. Canada Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 141. Mexico Oncology Pharmaceuticals Sales, by Type K Tons (2013-2018)
  • Table 142. Mexico Oncology Pharmaceuticals Sales, by Application K Tons (2013-2018)
  • Table 143. Oncology Pharmaceuticals: by Type(USD/Units)
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Oncology Pharmaceuticals: by Type(USD Million)
  • Table 157. Oncology Pharmaceuticals Chemotherapy , by Region USD Million (2019-2024)
  • Table 158. Oncology Pharmaceuticals Targeted Therapy , by Region USD Million (2019-2024)
  • Table 159. Oncology Pharmaceuticals Immunotherapy , by Region USD Million (2019-2024)
  • Table 160. Oncology Pharmaceuticals Hormonal Therapy , by Region USD Million (2019-2024)
  • Table 161. Oncology Pharmaceuticals Others , by Region USD Million (2019-2024)
  • Table 162. Oncology Pharmaceuticals: by Application(USD Million)
  • Table 163. Oncology Pharmaceuticals Breast Cancer , by Region USD Million (2019-2024)
  • Table 164. Oncology Pharmaceuticals Blood Cancer , by Region USD Million (2019-2024)
  • Table 165. Oncology Pharmaceuticals Colorectal , by Region USD Million (2019-2024)
  • Table 166. Oncology Pharmaceuticals Melanoma , by Region USD Million (2019-2024)
  • Table 167. Oncology Pharmaceuticals Others , by Region USD Million (2019-2024)
  • Table 168. South America Oncology Pharmaceuticals, by Country USD Million (2019-2024)
  • Table 169. South America Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 170. South America Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 171. Brazil Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 172. Brazil Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 173. Argentina Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 174. Argentina Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 175. Rest of South America Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 176. Rest of South America Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 177. Asia Pacific Oncology Pharmaceuticals, by Country USD Million (2019-2024)
  • Table 178. Asia Pacific Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 179. Asia Pacific Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 180. China Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 181. China Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 182. Japan Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 183. Japan Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 184. India Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 185. India Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 186. South Korea Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 187. South Korea Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 188. Taiwan Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 189. Taiwan Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 190. Australia Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 191. Australia Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 192. Rest of Asia-Pacific Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 193. Rest of Asia-Pacific Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 194. Europe Oncology Pharmaceuticals, by Country USD Million (2019-2024)
  • Table 195. Europe Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 196. Europe Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 197. Germany Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 198. Germany Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 199. France Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 200. France Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 201. Italy Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 202. Italy Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 203. United Kingdom Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 204. United Kingdom Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 205. Netherlands Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 206. Netherlands Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 207. Switzerland Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 208. Switzerland Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 209. Rest of Europe Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 210. Rest of Europe Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 211. MEA Oncology Pharmaceuticals, by Country USD Million (2019-2024)
  • Table 212. MEA Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 213. MEA Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 214. Middle East Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 215. Middle East Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 216. Africa Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 217. Africa Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 218. North America Oncology Pharmaceuticals, by Country USD Million (2019-2024)
  • Table 219. North America Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 220. North America Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 221. United States Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 222. United States Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 223. Canada Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 224. Canada Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 225. Mexico Oncology Pharmaceuticals, by Type USD Million (2019-2024)
  • Table 226. Mexico Oncology Pharmaceuticals, by Application USD Million (2019-2024)
  • Table 227. Oncology Pharmaceuticals Sales: by Type(K Tons)
  • Table 228. Oncology Pharmaceuticals Sales Chemotherapy , by Region K Tons (2019-2024)
  • Table 229. Oncology Pharmaceuticals Sales Targeted Therapy , by Region K Tons (2019-2024)
  • Table 230. Oncology Pharmaceuticals Sales Immunotherapy , by Region K Tons (2019-2024)
  • Table 231. Oncology Pharmaceuticals Sales Hormonal Therapy , by Region K Tons (2019-2024)
  • Table 232. Oncology Pharmaceuticals Sales Others , by Region K Tons (2019-2024)
  • Table 233. Oncology Pharmaceuticals Sales: by Application(K Tons)
  • Table 234. Oncology Pharmaceuticals Sales Breast Cancer , by Region K Tons (2019-2024)
  • Table 235. Oncology Pharmaceuticals Sales Blood Cancer , by Region K Tons (2019-2024)
  • Table 236. Oncology Pharmaceuticals Sales Colorectal , by Region K Tons (2019-2024)
  • Table 237. Oncology Pharmaceuticals Sales Melanoma , by Region K Tons (2019-2024)
  • Table 238. Oncology Pharmaceuticals Sales Others , by Region K Tons (2019-2024)
  • Table 239. South America Oncology Pharmaceuticals Sales, by Country K Tons (2019-2024)
  • Table 240. South America Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 241. South America Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 242. Brazil Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 243. Brazil Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 244. Argentina Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 245. Argentina Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 246. Rest of South America Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 247. Rest of South America Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 248. Asia Pacific Oncology Pharmaceuticals Sales, by Country K Tons (2019-2024)
  • Table 249. Asia Pacific Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 250. Asia Pacific Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 251. China Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 252. China Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 253. Japan Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 254. Japan Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 255. India Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 256. India Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 257. South Korea Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 258. South Korea Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 259. Taiwan Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 260. Taiwan Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 261. Australia Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 262. Australia Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 263. Rest of Asia-Pacific Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 264. Rest of Asia-Pacific Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 265. Europe Oncology Pharmaceuticals Sales, by Country K Tons (2019-2024)
  • Table 266. Europe Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 267. Europe Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 268. Germany Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 269. Germany Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 270. France Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 271. France Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 272. Italy Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 273. Italy Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 274. United Kingdom Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 275. United Kingdom Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 276. Netherlands Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 277. Netherlands Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 278. Switzerland Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 279. Switzerland Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 280. Rest of Europe Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 281. Rest of Europe Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 282. MEA Oncology Pharmaceuticals Sales, by Country K Tons (2019-2024)
  • Table 283. MEA Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 284. MEA Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 285. Middle East Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 286. Middle East Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 287. Africa Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 288. Africa Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 289. North America Oncology Pharmaceuticals Sales, by Country K Tons (2019-2024)
  • Table 290. North America Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 291. North America Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 292. United States Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 293. United States Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 294. Canada Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 295. Canada Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 296. Mexico Oncology Pharmaceuticals Sales, by Type K Tons (2019-2024)
  • Table 297. Mexico Oncology Pharmaceuticals Sales, by Application K Tons (2019-2024)
  • Table 298. Oncology Pharmaceuticals: by Type(USD/Units)
  • Table 299. Research Programs/Design for This Report
  • Table 300. Key Data Information from Secondary Sources
  • Table 301. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncology Pharmaceuticals: by Type USD Million (2013-2018)
  • Figure 5. Global Oncology Pharmaceuticals: by Application USD Million (2013-2018)
  • Figure 6. South America Oncology Pharmaceuticals Share (%), by Country
  • Figure 7. Asia Pacific Oncology Pharmaceuticals Share (%), by Country
  • Figure 8. Europe Oncology Pharmaceuticals Share (%), by Country
  • Figure 9. MEA Oncology Pharmaceuticals Share (%), by Country
  • Figure 10. North America Oncology Pharmaceuticals Share (%), by Country
  • Figure 11. Global Oncology Pharmaceuticals: by Type K Tons (2013-2018)
  • Figure 12. Global Oncology Pharmaceuticals: by Application K Tons (2013-2018)
  • Figure 13. South America Oncology Pharmaceuticals Share (%), by Country
  • Figure 14. Asia Pacific Oncology Pharmaceuticals Share (%), by Country
  • Figure 15. Europe Oncology Pharmaceuticals Share (%), by Country
  • Figure 16. MEA Oncology Pharmaceuticals Share (%), by Country
  • Figure 17. North America Oncology Pharmaceuticals Share (%), by Country
  • Figure 18. Global Oncology Pharmaceuticals: by Type USD/Units (2013-2018)
  • Figure 19. Global Oncology Pharmaceuticals share by Players 2018 (%)
  • Figure 20. Global Oncology Pharmaceuticals share by Players (Top 3) 2018(%)
  • Figure 21. Global Oncology Pharmaceuticals share by Players (Top 5) 2018(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2018
  • Figure 25. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis International AG (Switzerland) Revenue: by Geography 2018
  • Figure 27. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Celgene Corporation (United States) Revenue: by Geography 2018
  • Figure 29. Janssen Pharmaceutical (Belgium) Revenue, Net Income and Gross profit
  • Figure 30. Janssen Pharmaceutical (Belgium) Revenue: by Geography 2018
  • Figure 31. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol-Myers Squibb (United States) Revenue: by Geography 2018
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co. (United States) Revenue: by Geography 2018
  • Figure 37. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 39. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. AbbVie, Inc. (United States) Revenue: by Geography 2018
  • Figure 41. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 43. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 45. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Amgen Inc. (United States) Revenue: by Geography 2018
  • Figure 47. Global Oncology Pharmaceuticals: by Type USD Million (2019-2024)
  • Figure 48. Global Oncology Pharmaceuticals: by Application USD Million (2019-2024)
  • Figure 49. South America Oncology Pharmaceuticals Share (%), by Country
  • Figure 50. Asia Pacific Oncology Pharmaceuticals Share (%), by Country
  • Figure 51. Europe Oncology Pharmaceuticals Share (%), by Country
  • Figure 52. MEA Oncology Pharmaceuticals Share (%), by Country
  • Figure 53. North America Oncology Pharmaceuticals Share (%), by Country
  • Figure 54. Global Oncology Pharmaceuticals: by Type K Tons (2019-2024)
  • Figure 55. Global Oncology Pharmaceuticals: by Application K Tons (2019-2024)
  • Figure 56. South America Oncology Pharmaceuticals Share (%), by Country
  • Figure 57. Asia Pacific Oncology Pharmaceuticals Share (%), by Country
  • Figure 58. Europe Oncology Pharmaceuticals Share (%), by Country
  • Figure 59. MEA Oncology Pharmaceuticals Share (%), by Country
  • Figure 60. North America Oncology Pharmaceuticals Share (%), by Country
  • Figure 61. Global Oncology Pharmaceuticals: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis International AG (Switzerland)
  • Celgene Corporation (United States)
  • Janssen Pharmaceutical (Belgium)
  • Bristol-Myers Squibb (United States)
  • Pfizer Inc. (United States)
  • Merck & Co. (United States)
  • Eli Lilly and Company (United States)
  • AbbVie, Inc. (United States)
  • AstraZeneca plc. (United Kingdom)
  • Bayer AG (Germany)
  • Amgen Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation